FDA clears Tandem’s Control-IQ+ for type 2 diabetes treatment

Tandem Diabetes (TNDM) Care announced that its next-generation automated insulin delivery AID algorithm, Control-IQ+ technology or Control-IQ+ , has been cleared by the United States Food and Drug Administration FDA for use by people with type 2 diabetes ages 18 and older. Control-IQ+, already cleared for use by people with type 1 diabetes, builds on the company’s proven Control-IQ algorithm and includes enhancements to accommodate input of expanded weight and total daily insulin ranges. Control-IQ+ is expected to be available for new and existing customers in the United States in March 2025.”We have seen firsthand, through numerous clinical and real-world studies, how Control-IQ has improved health outcomes and quality of life for our users with type 1 diabetes” “We have seen firsthand, through numerous clinical and real-world studies, how Control-IQ has improved health outcomes and quality of life for our users with type 1 diabetes,” said John Sheridan, president and chief executive officer. “It is a natural evolution of our mission to bring the same AID technology that helped to make Tandem the #1 recommended insulin pump brand by both healthcare providers and people living with type 1 diabetes to adults with type 2.